Pillar Clinical Research, LLC

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Depression3 trials
• Schizophrenia3 trials
• Autism2 trials
• Bipolar disorder2 trials

Phase

• Phase 34 trials
• Phase 23 trials
• Phase 11 trial

Status

• Completed4 trials
• Recruiting4 trials

Lead sponsor

• Intra-Cellular Therapies, Inc.3 trials
• Biohaven Therapeutics Ltd.2 trials
• atai Therapeutics, Inc.1 trial
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial
• Leal Therapeutics, Inc1 trial

Running trials

• Recruiting

  A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia

  NCT07734493· Phase 1· Leal Therapeutics, Inc· Source

  Contact: Leslie Smith

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Irritability Associated With Autism Spectrum Disorder (ASD) in Pediatric Patients

  NCT06706674· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients

  NCT06372964· Phase 3· Intra-Cellular Therapies, Inc.· Source

• Recruiting

  Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder

  NCT06229210· Phase 3· Intra-Cellular Therapies, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Autism2 recruiting
• Bipolar disorder2 recruiting
• Schizophrenia2 recruiting

Closed trials

• Completed

  A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA)

  NCT06524830· Phase 2· atai Therapeutics, Inc.· Source

• Completed

  Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

  NCT06423781· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  Efficacy and Safety Study of BHV-7000 Monotherapy in Major Depression

  NCT06419608· Phase 2· Biohaven Therapeutics Ltd.· Source

• Completed

  A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

  NCT05145413· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source